| (Values in U.S. Thousands) | Dec, 2016 | Sep, 2016 | Jun, 2016 | Mar, 2016 | Dec, 2015 |
| Sales | -9,999,000 | 890 | 870 | 820 | 660 |
| Sales Growth | -1,123,583.15% | +2.30% | +6.10% | +24.24% | +32.00% |
| Net Income | -9,999,000 | -1,840 | -2,510 | -2,760 | -2,980 |
| Net Income Growth | -543,323.91% | +26.69% | +9.06% | +7.38% | +5.40% |
Signal Genetics Cmn (SGNL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Signal Genetics, Inc. is an emerging commercial stage, molecular diagnostic company. It is focused on providing diagnostic services that help physicians in decision making for the care of cancer patients. The Company's flagship diagnostic service is the Myeloma Prognostic Risk Signature, or MyPRS (TM). Signal Genetics, Inc. is headquartered in New York.